Effect of Bevacizumab, a Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, on Peritoneal Metastasis of MNK-45P Human Gastric Cancer in Mice

Ninomiya, Shigeo; Ito, Masafumi; Tajima, Masaaki; Ali, Anwar; Ueda, Y.; Shiraishi, Norio; Kitano, Seigo

doi:10.1016/j.jss.2008.08.017

Cited by 29 publications

(16 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As noted previously, bevacizumab binds human VEGF-A and prevents its binding to VEGF receptors. In one study, intraperitoneal administration of bevacizumab inhibited peritoneal metastasis and reduced malignant ascites when MKN-45P human gastric cancer cells were injected into the peritoneal cavity of mice [40]. DC101 is a monoclonal antibody targeting mouse VEGFR-2.…”

Section: Vegf-a Inhibition In Gastric Cancermentioning

confidence: 99%

Vascular Endothelial Growth Factor A Inhibition in Gastric Cancer

et al. 2014

View full text Add to dashboard Cite

Section: Vegf-a Inhibition In Gastric Cancermentioning

confidence: 99%

Vascular Endothelial Growth Factor A Inhibition in Gastric Cancer

et al. 2014

View full text Add to dashboard Cite

“…Several studies using mouse models indicate that intraperitoneal (regional) bevacizumab could be useful for peritoneal metastasis 23,39. In clinical case reports, bevacizumab was also administrated regionally for patients with malignant ascites 40,41.…”

Section: Discussionmentioning

confidence: 99%

VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody

Fushida¹,

Oyama²,

Koyama³

et al. 2013

OTT

View full text Add to dashboard Cite

BackgroundIn gastric cancer, poor prognosis is associated with peritoneal dissemination, which often accompanies malignant ascites. We searched for a target molecule in peritoneal metastasis and investigated its clinical utility as a biomarker.MethodsBiopsy specimens from both primary lesions and peritoneal metastasis, and if possible, malignant ascites, were obtained from 40 patients with gastric cancer. Vascular endothelial growth factor (VEGF) expression was analyzed by immunohistochemical staining and enzyme-linked immunosorbent assay.ResultsVEGF expression was seen in 70% of peritoneal samples. Of the 40 patients, 35 had malignant ascites. These 35 patients were divided into two groups: 15 with ascites found beyond the pelvic cavity (large group) and 20 whose ascites were within the pelvic cavity (small group). The two groups did not significantly differ by serum VEGF levels, but ascites VEGF levels in the large group were significantly higher than in the small group (P < 0.0001). Serum VEGF and ascites VEGF levels were highly correlated in the large group (r = 0.686). A high ascites VEGF level was found to be a risk factor for survival (P = 0.045). We include a report of a patient with chemoresistant refractory gastric cancer and symptomatic ascites who obtained 8 months of palliation from systemic bevacizumab.ConclusionAnti-VEGF therapies are promising, and the ascites VEGF level is an important marker in managing patients with gastric cancer and peritoneal metastasis.

show abstract

“…In view of the limitations of the effects of IP chemotherapy for PC with LN metastasis and the frequent LN metastasis in gastric cancer with PC, other treatment strategies should be employed for this disease [5,6]. In terms of newer treatment strategies, it has been shown that angiogenesis is important for the development of gastric cancer PC, and the inhibition of angiogenesis is reported to be effective for the management of PC [17][18][19]. Yagi et al [20] reported that, in a PC model for gastric cancer, systemic administration of a monoclonal antibody against vascular endothelial growth factor (VEGF) was effective in reducing ascites and inhibiting tumor growth.…”

Section: Discussionmentioning

confidence: 99%